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Introduction: Pain in osteoarthritis (OA) has been classically attributed to joint structural damage. Disparity
between the degree of radiographic structural damage and the severity of symptoms implies that factors other
than the joint pathology itself contribute to the pain. Peripheral and central sensitization have been suggested as
two of the underlying mechanisms that contribute to pain in OA. The aim of this study was to explore in
symptomatic knee OA patients, the structural changes assessed by magnetic resonance imaging (MRI) that could
be used as markers of neuropathic pain (NP).
Methods: This cross-sectional observational pilot study included 50 knee OA patients with moderate to severe pain
(VAS ≥40) in the target knee. The presence of NP was determined based on the PainDETECT questionnaire. Among
the 50 patients included, 25 had PainDETECT score ≤12 (unlikely NP), 9 had PainDETECT score between 13 and 18
(uncertain NP) and 16 had PainDETECT score ≥19 (likely NP). WOMAC, PainDETECT, and VAS pain scores as well as
knee MRI were assessed.
Results: Data showed no significant difference in demographic characteristics between the three groups. However,
a positive and statistically significant association was found between the WOMAC pain (P <0.001), function
(P <0.001), stiffness (P = 0.007) and total (P <0.001) scores as well as higher VAS pain score (P = 0.023), and
PainDETECT scores. Although no difference was found in the cartilage volume between groups, the presence of
meniscal extrusion in both medial (P = 0.006) and lateral (P = 0.023) compartments, and presence of meniscal tears
in the lateral compartment (P = 0.011), were significantly associated with increasing PainDETECT score. Moreover,
the presence of bone marrow lesions in the lateral plateau and the extent of the synovial membrane thickness in
the lateral recess were associated with increasing PainDETECT scores (P = 0.032, P = 0.027, respectively).
Conclusions: In this study, meniscal lesions, particularly extrusion, were found to be among the strongest risk
factors for NP in knee OA patients.
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Pain in osteoarthritis (OA) has been classically attributed
to joint structural damage, and nearly all therapeutic
strategies have been aimed at treating the pain derived
from the joint. However, disparity between the degree of
radiographic structural damage and the severity of symp-
toms, such as pain and functional limitations in OA pa-
tients, implies that factors other than the joint pathology
itself, also contribute to the pain. Peripheral and central
sensitizations have been suggested as two of the underlying
mechanisms of pain in OA. Indeed, OA patients have been
found to experience both nociceptive and neuropathic pain
(NP) to varying degrees [1-5]. The peripheral nociceptors
may be sensitized by, for example, inflamed synovium and
damaged subchondral bone [5]. Continuous and intense
nociceptive input from the OA knee joint may drive cen-
tral sensitization, which may arise from chronic nociceptor
stimulation and subsequent modification of central pain-
transmitting neurons, and may be clinically associated with
NP qualities [1,2]. The diagnosis of NP is clinical and based
on medical history, physical examination, and ancillary
tests [6]. One such test, the PainDETECT, is a patient-
report questionnaire extensively validated for the diagnosis
of NP in various chronic pain conditions [7-11]. Higher
scores suggest the likelihood of NP while lower scores are
suggestive of a nociceptive pain. Hence, an NP component
is unlikely if the score is ≤12, uncertain if the score is 13 to
18, and likely if the score is ≥19 [7].
This cross-sectional study thus aimed at investigating,
in knee OA patients with moderate to severe pain (visual
analog scale (VAS) ≥40 mm), the structural changes
assessed by magnetic resonance imaging (MRI) that could
be used as markers of uncertain (PainDETECT >12) or
likely (PainDETECT ≥19) NP.
Methods
Study population and design
This study is a multicentre, cross-sectional, single-blinded
observational pilot study. The presence of NP was deter-
mined based on use of the PainDETECT questionnaire
(score 0 to 38) [7-11]. The classification method defines
NP as unlikely (score ≤12), uncertain (score 13 to 18), or
likely (≥19). In this study, a total of 50 knee OA patients
with moderate to severe pain (VAS ≥40) in the most pain-
ful knee were enrolled, 25 having PainDETECT score ≤12,
9 having PainDETECT score between 13 and 18, and 16
having PainDETECT score ≥19. Since this is a pilot study,
the number of patients was arbitrarily determined at 50,
which represents 25 patients with unlikely NP and 25 pa-
tients with uncertain or likely NP, a number deemed suffi-
cient to identify the knee OA structural changes that
could be preferentially associated with NP.
Subjects aged 40 years and older, followed in ambula-
tory clinics, with a diagnosis of primary knee OAaccording to the American College of Rheumatology
criteria, of Kellgren-Lawrence (KL) radiological grades 2
and 3, and being symptomatic for at least 1 month out
of the 3 months preceding the study, and VAS pain
score while walking on a flat surface ≥40 mm, were eli-
gible to be included in the study.
Subjects were excluded from the study if they met any
of the following criteria at the beginning of, or during,
the study: other bone or articular diseases (antecedents
and/or current signs), isolated knee OA in the lateral
compartment only defined by joint space loss, surgery
on the target knee, comorbidities that restrict knee func-
tion, having taken any investigational drug within 30 days
or 5 half-lives (whichever is greater) prior to entering the
study, inability to give informed consent, meeting any
contra-indication related to MRI, having taken either cor-
ticosteroids (oral, injectable or intra-articular injection of
the target knee during the 12 weeks preceding the study)
or intra-articular injections of hyaluronic acid in the target
knee during the 26 weeks preceding the study.
This study, registered at ClinicalTrials.gov (NCT01
733277), was approved by the ethics committee IRB Ser-
vices (Institutional Review Board Services), Aurora, ON,
Canada. Written informed consent was obtained from
all participants.
Study visit: clinical, biological and X-ray outcomes
The clinical characteristics included demographic data,
the Western Ontario and McMasters Universities Osteo-
arthritis Index (WOMAC) questionnaire [12] and the
VAS for global knee pain (0 mm = no pain, 100 mm =
most severe pain) within the last week, and the PainDE-
TECT questionnaire completed at the study visit. Blood
tests for sedimentation rate and C-reactive protein (CRP)
were done. Knee X-rays taken within the last 12 months
were used to verify that the subject satisfied radiological
criteria of inclusion (KL grades 2 and 3).
MRI acquisition and determination of structural changes
MRI of the target knee was performed no more than
21 days after the study visit. The MRI acquisitions were
performed on Philips Achieva 3 T units (Philips Health-
Care, Markham, ON, Canada). The MRI examination
comprised the following sequences: sagittal proton
density-weighted fast spin-echo sequence with fat
suppression (PD-FSE) (TR/TE, 3,550/25 ms; flip angle, 90
degrees; slice thickness/gap, 3/0 mm; excitation number,
1; matrix size, 348 × 348 px; field of view, 140 mm;
resolution, 0.398/0.398 mm; receiver bandwidth, 192 Hz/
pixel; phase direction, S/I); sagittal three-dimensional
intermediate-weighted fast spin-echo sequence with fat
suppression (VISTA-SPAIR) (TR/TE, 1,500/30 ms; flip
angle, 90 degrees; slice thickness/gap, 0.6/0 mm; excita-
tion number, 1; matrix size, 232 × 232 px; field of view,
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width, 380 Hz/pixel; phase direction, A/P); and axial
T1-weighted gradient-echo sequence non-fat suppressed
(In-Out Phase) (TR/TE, 450/3.45 to 4.60 ms; slice thick-
ness/gap, 3.0/0 mm; excitation number, 1; matrix size,
256 × 256 px; field of view, 180 mm; resolution, 0.25/
0.25 mm; phase direction, L/R).
The cartilage volume was measured using the VISTA-
SPAIR sequence and values determined with ArthroLab’s
fully automated quantitative MRI (qMRI) system (Arthro-
Lab Inc, Montreal, QC, Canada) as described [13]. Menis-
cal tears were assessed with a fluid-sensitive sequence
(PD-FSE) as recommended [14,15] and scored as absence
(−) or presence (+) of a tear detected in any of the three
segments (anterior horn, body, posterior horn) of the me-
niscus. Meniscal extrusion was assessed using the VISTA-
SPAIR sequence, which allows for a precise evaluation of
the extent of the extrusion, and scored as absence (−) or
presence (+) of partial or complete extrusion detected in
any of the three segments of the meniscus as described
[14,16]. Presence of bone marrow lesions (BMLs) was
assessed with the PD-FSE sequence and evaluated as de-
scribed [17]. The synovial membrane thickness (mm) was
measured with the In-Out Phase sequence and measured
in four subregions (medial and lateral articular recess and
medial and lateral border of the suprapatellar bursa) as de-
scribed [17,18]. Of note, the measurement of the synovial
membrane thickness according to this method relies on
the presence of synovial fluid, as assessed with the PS-FSE
sequence, to localize the membrane in the different re-
gions of interest. Thus, absence of synovial fluid that
occurs, especially for the medial suprapatellar bursa, ac-
counts for some missing values. The synovial effusion vol-
ume was assessed in its entirety using ArthroLab’s fully
automated qMRI system as described [19]. The evaluation
of the structural changes was done under blinded condi-
tions of patient identification and clinical data.
Statistical analysis
This exploratory study aimed to correlate the knee OA
structural changes as assessed by quantitative and semi-
quantitative MRI scoring systems (cartilage volume,
meniscal extrusion, BMLs, synovitis, and synovial effu-
sion) with the presence of NP, by comparing the three
study groups stratified according to PainDETECT scores
(≤12, 13 to 18, and ≥19). Comparison of the demo-
graphic characteristics of the three study groups was car-
ried out using the Kruskal-Wallis test for continuous
variables and the chi-square test (or Fisher’s exact test)
for categorical variables. Comparison of the clinical and
MRI characteristics was carried out using the Jonckheere-
Terpstra trend test for continuous variables and the
Cochran-Armitage trend test for categorical variables. A
P value ≤0.05 was considered statistically significant. Allstatistical analyses were done using SAS software, version
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Demographics
The demographic characteristics of the three groups did
not differ (Table 1). No statistical difference was found
between PainDETECT groups with regard to the KL scores
(Table 1). None of the patients received treatment for NP
such as tricyclic antidepressants (TCAs), selective sero-
tonin and norepinephrine reuptake inhibitors (SSRIs and
SNRIs, respectively) or anticonvulsants (for example cal-
cium channel α2δ ligands).
WOMAC, VAS, and PainDETECT pain scores
A significant association was found between the WOMAC
pain (P <0.001), function (P <0.001), stiffness (P = 0.007)
and total (P <0.001) scores and higher VAS pain (P = 0.023)
and PainDETECT scores (Table 1).
Inflammatory biomarkers
No association was found between the sedimentation rate,
the CRP values, and the PainDETECT scores (Table 1).
Knee structural changes assessed by MRI
Cartilage
No association was found between the cartilage volume
and the PainDETECT scores (Table 2).
Meniscus
The presence of meniscal extrusion in both medial (P =
0.006) and lateral (P = 0.023) compartments was found to
be significantly associated with increasing PainDETECT
scores (Table 2). The presence of meniscal tears in the lat-
eral compartment (P = 0.011) was also significantly associ-
ated with PainDETECT scores (Table 2).
Bone marrow lesions
Whereas no association between the presence of BMLs
and the PainDETECT scores was found for the medial
compartment, the association was significant in the lat-
eral plateau (P = 0.032, Table 2).
Synovial membrane thickness/synovial effusion
No association was found between the synovial mem-
brane thickness or synovial effusion size and the Pain-
DETECT scores, except for the synovial membrane
thickness in the lateral recess (P = 0.027) (Table 2).
Discussion
The aim of this cross-sectional pilot study was to ex-
plore in symptomatic knee OA patients the relationship
between structural changes assessed by MRI and the
presence of NP.









Age, years 66 ± 9 63 ± 9 67 ± 7 0.392*
Female, n (%) 18 (72%) 5 (56%) 10 (63%) 0.629‡
Weight, kg 82.5 ± 14.1 81.0 ± 10.6 87.0 ± 18.9 0.587*
OA duration, years 7.7 ± 8.1 7.4 ± 6.6 8.1 ± 4.6 0.528*
BMI, kg/m2 31 ± 6 29.9 ± 3 33 ± 6 0.558*
NSAID users, n (%) 3 (12%) 0 (0%) 5 (31%) 0.114¶
PainDETECT 8.1 ± 2.6 15.6 ± 1.1 24.2 ± 4.2 <0.001♦
WOMAC
Pain (0–100) 43 ± 17 50 ± 13 65 ± 14 <0.001♦
Function (0–100) 45 ± 23 52 ± 15 68 ± 14 <0.001♦
Stiffness (0–100) 51 ± 24 49 ± 18 69 ± 16 0.007♦
Total (0–100) 45 ± 21 51 ± 14 68 ± 13 <0.001♦
VAS pain (0–100 mm) 62 ± 14 62 ± 13 69 ± 13 0.023♦
Kellgren-Lawrence score 0.068†§
2 14 (56%) 5 (56%) 5 (31%)
3 11 (44%) 4 (44%) 11 (69%)
Inflammatory biomarkers
Sedimentation rate, mm 12.4 ± 9.0 12.6 ± 5.5 15.2 ± 20.8 0.406♦
CRP, mg/l 4.3 ± 2.9 6.8 ± 9.1 5.0 ± 4.7 0.432♦
Results are shown as mean ± standard deviation (SD) unless otherwise indicated. P values were assessed using the *Kruskal-Wallis test, the ‡chi-square test, the
¶Fisher’s exact test, the ♦Jonckheere-Terpstra test for trend, or the †Cochran-Armitage trend test; §Includes both Kellgren-Lawrence scores. n, number of participants;
OA, osteoarthritis; BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index (each
subscale, 100 =worst score; total scale, 100 =worst score); VAS, visual analog scale (0 mm= no pain, 100 mm=most severe pain); CRP, C-reactive protein.
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patients with moderate to severe pain level, data first in-
dicate a positive relationship between the level of OA
symptoms and NP, in which the WOMAC scores as well
as the VAS pain score were associated with the PainDE-
TECT scores. Importantly, data also showed a greater
likelihood of NP in patients with meniscal extrusion and
lateral meniscal tears. These thus suggest that knee OA
patients with a neuropathic component of pain have more
severe symptoms, which appear related to meniscal le-
sions, more specifically extrusion, and are reflected, to a
certain extent, by a trend toward a greater consumption of
non-steroidal anti-inflammatory drugs (NSAIDs).
A higher WOMAC pain score in OA patients with a
neuropathic component of pain has been previously re-
ported [4] and could possibly explain the greater level of
central sensitization that may have occurred. There was,
however, no evidence in the present study, based on the
current MRI findings, of an association with a more se-
vere disease, which is in agreement with the previous
report [4]. Results of this study also concur with the re-
port of Murphy et al. [20] to the effect that the level of
centrally mediated symptoms was likely independently
associated with the pain severity. One cannot excludethe fact that nociception may have also played a role in
the genesis of local pain and peripheral hyperalgia in the
OA knee joint as well as central sensitization related to
prolonged neuronal discharges [21]. The combination of
peripheral and central pain mechanisms may possibly ex-
plain, at least in part, the discrepancy reported between
the severity of OA changes and the pain intensity.
The mechanisms underlying NP-like symptoms in OA
are still poorly understood. OA pain likely includes both
nociceptive and neuropathic components. It has been
suggested that the local damage to innervation as well as
other joint structures may cause damage to peripheral
nerves [3]. In this context, the association found between
the presence of NP and BMLs and synovitis (synovial
membrane thickness) in the lateral compartment is also
very interesting. Although BMLs have been associated
with knee pain [22-24], no report so far has related those
changes with NP. A definite study with a larger number of
patients would provide a better understanding of the
current finding as well as its true meaning. A similar com-
ment applies to the observation regarding the increase in
synovial membrane thickness in the lateral compartment,
as it is believed that synovial inflammation could sensitize
peripheral nociceptors [25]. Therefore, it would seem








MRI cartilage volume (mm3)
Global knee 12,439 ± 2,451 12,181 ± 3,894 12,280 ± 2,414 0.347
Femur 8,872 ± 1,799 8,998 ± 2,769 8,784 ± 1,950 0.381
Condyle 5,873 ± 1,220 5,678 ± 1,784 5,825 ± 1,552 0.288
Plateau 3,567 ± 907 3,183 ± 1,467 3,497 ± 727 0.395
Medial compartment 6,232 ± 1,258 5,919 ± 2,098 6,101 ± 1,473 0.333
Femur 4,594 ± 884 4,602 ± 1,451 4,474 ± 1,103 0.288
Condyle 3,094 ± 541 2,878 ± 912 3,043 ± 915 0.172
Plateau 1,639 ± 516 1,317 ± 791 1,626 ± 524 0.424
Lateral compartment 6,207 ± 1,404 6,207 ± 1,404 6,180 ± 1,476 0.300
Femur 4,278 ± 1,030 4,397 ± 1,415 4,309 ± 1,002 0.445
Condyle 2,779 ± 768 2,800 ± 1,019 2,782 ± 798 0.496
Plateau 1,928 ± 595 1,865 ± 766 1,870 ± 738 0.720
Meniscal extrusion (presence)
Medial compartment 7 (28%) 3 (33%) 11 (69%) 0.006†
Lateral compartment 1 (4%) 1 (11%) 4 (25%) 0.023†
Meniscal tears (presence)
Medial compartment 14 (56%) 5 (56%) 10 (63%) 0.347†
Lateral compartment 3 (12%) 1 (11%) 7 (44%) 0.011†
Bone marrow lesions (presence)
Medial compartment 13 (54%)a 8 (89%) 10 (63%) 0.246†
Condyle 4 (17%)a 1 (11%) 3 (19%) 0.447†
Plateau 12 (50%)a 7 (78%) 10 (63%) 0.186†
Lateral compartment 9 (38%)a 5 (56%) 7 (44%) 0.321†
Condyle 1 (4%)a 0 (0%) 1 (6%) 0.395†
Plateau 8 (33%)a 5 (56%) 10 (63%) 0.032†
Synovial membrane thickness (mm)
Global 2.23 ± 0.66 2.32 ± 0.51 2.13 ± 0.52 0.427
Medial compartment 2.27 ± 1.28b 2.14 ± 0.58 1.97 ± 0.42c 0.390
Medial recess 2.02 ± 0.96d 1.91 ± 0.62 1.93 ± 0.82c 0.399
Medial suprapatellar bursa 2.89 ± 1.57e 2.73 ± 1.00f 2.13 ± 0.68e 0.111
Lateral compartment 2.21 ± 0.75 2.47 ± 0.68 2.19 ± 0.73 0.402
Lateral recess 1.90 ± 0.64a 2.07 ± 0.76 2.15 ± 0.55c 0.027
Lateral suprapatellar bursa 2.64 ± 1.42b 2.96 ± 1.15g 2.26 ± 1.18 0.228
Synovial effusion (ml) 11.22 ± 7.74 14.40 ± 10.3 12.40 ± 6.40 0.202
Results are shown as mean ± standard deviation (SD) unless otherwise indicated. P values were assessed using the ♦Jonckheere-Terpstra test for trend, and the
†Cochran-Armitage trend test. a, n = 24; b, n = 22; c, n = 15; d, n = 21; e, n = 12; f, n = 6; g, n = 8. MRI, magnetic resonance imaging; OA, osteoarthritis; NP, neuropathic
pain; n, number of participants.
Roubille et al. Arthritis Research & Therapy  (2014) 16:507 Page 5 of 7appropriate and logical to pursue this avenue of research
in the future.
The association of knee pain with meniscal extrusion
assessed by MRI in OA patients was recently reported
[26]. A few possible explanations for the relationship
between meniscal extrusion and knee pain are asfollows. First, the association between meniscal extru-
sion and BMLs, a known source of pain [26], could
possibly be due to the loss of mechanical protection pro-
vided by the meniscus. Second, it could be, as recently
reported [27], that the increased vascular penetration
and sensory nerve densities in the OA medial meniscus
Roubille et al. Arthritis Research & Therapy  (2014) 16:507 Page 6 of 7suggest a potential role of meniscal sensory nerve
growth in knee OA pain, and could have contributed to
the neuropathic component of the pain. Another pos-
sible explanation may be the mechanical stretching of
the joint capsule, a richly innervated tissue, by the bul-
ging meniscus. Our finding of an association between
NP and lateral meniscal tear is somewhat unexpected as
literature indicates that meniscal tears are not usually as-
sociated with symptoms [28]. Perhaps this finding is due
to the role of possible confounding factors that will have
to be further explored in a comprehensive study with a
larger number of patients.
It is noteworthy that very few data exist regarding the
relationship between meniscal lesions and NP in knee
OA and this is a promising field of future research. The
present study is particularly interesting as it is the first
to report a clear association of meniscal lesions, more
specifically extrusion, with NP. The finding of the associ-
ation between the presence of meniscal extrusion and
the PainDETECT scores makes this structural alteration
a definite marker of NP. This finding is clinically rele-
vant for various reasons. First, it argues for a patho-
physiological relationship between NP and meniscal
extrusion in knee OA and supports the examination for
meniscal extrusion in knee OA patients with NP. This
suggests that in daily practice, the predominance of a
neuropathic component in such patients should encour-
age physicians to consider the use of MRI to establish a
proper diagnosis. Second, a diagnosis of meniscal extru-
sion may help to identify knee OA patients who are
more susceptible to benefit from a treatment aimed at
controlling their symptoms more specifically. There is
hope that this ‘personalized therapeutic management’
would avoid the prolonged use of anti-inflammatory
drugs or even narcotic analgesics, preventing potential
side effects, and that the patients would have a better
response to treatment. Future research might explore
whether managing meniscal extrusion, for instance with
arthroscopic meniscal repair or resection, in such pa-
tients with NP would be beneficial.
This pilot study has limitations, the first being that it
was an observational study and not a randomized con-
trolled trial, the second being the arbitrary determin-
ation of the sample and, third, the diagnosis of NP was
based solely on the PainDETECT questionnaire. How-
ever, as no gold standard test for NP diagnosis in OA is
yet recognized, this questionnaire was used, as in many
previous OA studies [4,29,30], since it provides the
greatest level of confidence. The relatively small sample
size may also be a limiting factor. Nonetheless, this MRI
study provides strong insight into the relationship be-
tween NP and meniscal lesions in knee OA, especially in
patients with higher PainDETECT scores, hence with
likely NP.Conclusions
In summary, the findings of this study show that in knee
OA patients, meniscal lesions are a definite major risk
factor for NP. BMLs and synovitis also seem to be, to a
certain extent, associated with NP; however, a definite
study is needed to fully address the question, as they
may be contributing factors in association with others.
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